• Dexamethasone dosing in newly diagnosed multiple myeloma, a new experimental model of X-linked sideroblastic anemia, and ciltacabtagene autoleucel in real-world myeloma treatment

  • Jan 2 2025
  • Length: 20 mins
  • Podcast

Dexamethasone dosing in newly diagnosed multiple myeloma, a new experimental model of X-linked sideroblastic anemia, and ciltacabtagene autoleucel in real-world myeloma treatment

Listen for free

View show details

  • Summary

  • In this week's episode, we’ll learn about the prevalence and impact of dexamethasone dose reductions during triple or quadruple therapy for newly diagnosed multiple myeloma, a conditional knockout mouse model for testing gene therapy in X-linked sideroblastic anemia, and real-world efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

    Featured Articles:

    • Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
    • An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA
    • Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
    Show More Show Less
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Dexamethasone dosing in newly diagnosed multiple myeloma, a new experimental model of X-linked sideroblastic anemia, and ciltacabtagene autoleucel in real-world myeloma treatment

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available